210 related articles for article (PubMed ID: 28994319)
1. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
Silberstein SD
Expert Opin Drug Saf; 2018 Jan; 17(1):89-97. PubMed ID: 28994319
[TBL] [Abstract][Full Text] [Related]
2. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
3. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
4. AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.
Silberstein S
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):821-832. PubMed ID: 28605258
[TBL] [Abstract][Full Text] [Related]
5. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
Cady R
Expert Opin Drug Deliv; 2015; 12(9):1565-77. PubMed ID: 26119828
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
7. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
[TBL] [Abstract][Full Text] [Related]
8. Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine.
Tepper SJ; Johnstone MR
Med Devices (Auckl); 2018; 11():147-156. PubMed ID: 29760572
[TBL] [Abstract][Full Text] [Related]
9. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
McGinley JS; Buse DC; Shulman KJ; Wirth RJ; Hugentobler E; Lipton RB
Headache; 2019 Jul; 59(7):1002-1013. PubMed ID: 31062349
[TBL] [Abstract][Full Text] [Related]
10. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications for breath-powered powder sumatriptan intranasal treatment.
Tepper SJ
Headache; 2013 Sep; 53(8):1341-9. PubMed ID: 23809006
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.
Cady R
Expert Opin Pharmacother; 2015; 16(13):2039-51. PubMed ID: 26255952
[TBL] [Abstract][Full Text] [Related]
13. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
Luthringer R; Djupesland PG; Sheldrake CD; Flint A; Boeijinga P; Danjou P; Demazières A; Hewson G
J Pharm Pharmacol; 2009 Sep; 61(9):1219-28. PubMed ID: 19703372
[TBL] [Abstract][Full Text] [Related]
14. AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.
Lipton RB; McGinley JS; Shulman KJ; Silberstein SD; Wirth RJ; Buse DC
Headache; 2018 Feb; 58(2):229-242. PubMed ID: 29034453
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine.
Al-Salama ZT; Scott LJ
Drugs; 2016 Oct; 76(15):1477-1484. PubMed ID: 27681528
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine.
Freitag FG; Shumate DA
Expert Rev Neurother; 2016 Jul; 16(7):743-7. PubMed ID: 27260875
[TBL] [Abstract][Full Text] [Related]
18. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
Rapoport AM; Freitag F; Pearlman SH
CNS Drugs; 2010 Nov; 24(11):929-40. PubMed ID: 20932065
[TBL] [Abstract][Full Text] [Related]
19. Sumatriptan iontophoretic transdermal system: a review of its use in patients with acute migraine.
Garnock-Jones KP
Drugs; 2013 Sep; 73(13):1483-90. PubMed ID: 23912626
[TBL] [Abstract][Full Text] [Related]
20. Zelrix: a novel transdermal formulation of sumatriptan.
Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
